vnu醫療技術

2018年5月23日

Myoscience公司今天宣布任命布萊恩·法利董事會主席和愛德華Kleinhans作為公司的臨時CEO。法利先生是一位資深的醫學技術行業高管建立和領導多次成功的醫療設備公司從早期到強勁的商業增長,上市、銷售的企業。Farley先生目前擔任董事會主席會也會Inc .的一個商業階段醫學技術公司集中在治療抑鬱症,Neurolutions Inc .)的董事,中風後康複的醫學技術公司開發解決方案。最近,法利先生擔任董事會主席聖猿醫療、公司並擔任公司的首席執行官從2010年到2015年,領先的公司在2015年初在成功的IPO。加入聖猿之前,法利先生的總裁兼首席執行官vnu醫療技術公司。他於1995年加入vnu的第一個員工,帶領公司成為市場領導者的靜脈功能不全的微創療法。Farley先生領導vnu在2004年成功上市,2009年6月,vnu Covidien出售。vnu之前,法利先生舉行各種管理和行政職位研發、臨床研究和商業發展Guidant公司和禮來公司和公司的醫療部門。Farley先生擁有工程學士學位和碩士學位電氣工程與生物醫學工程主要來自普渡大學。“我很高興任命布萊恩·法利作為Myoscience董事會主席。布萊恩是一個經驗豐富的高管與巨大的成功記錄。 We are excited to have Brian accept the position at this critical time for the company,” said Jan Pensaert (Valiance Asset Management, Ltd.), a member of the Board of Directors. “I am honored to assume the role of Chairman for Myoscience and help the Board of Directors and management through the Company’s next phase of business and commercial expansion,” said Mr. Farley. “The Myoscience team has built an extremely strong platform technology that targets peripheral nerve pain. The initial commercial focus in orthopedic pain management related to total knee replacement and osteoarthritis of the knee is in areas with significant clinical need and tremendous market opportunity. The company is at an exciting stage with early market adoption underway and facilitated by strong clinical evidence that shows the company’s iovera° product enables immediate pre- and post-operative pain relief, shortens the patient’s length of stay, and reduces opioid narcotic medication use. We are enthused about the near-term opportunities in these markets and expanding iovera° into other applications.” Mr. Kleinhans has been serving as the company’s Chief Business Officer since October, 2017. Prior to joining Myoscience, Mr. Kleinhans served as Corporate Strategy and Legal Adviser for Hansen Medical, Inc., advising the company on its sale to Auris Surgical Robotics for $80 million in July 2016. Prior to joining Hansen, Mr. Kleinhans served as Chief Operating Officer for Vaquero Capital and served as Vice President, General Counsel, at Care Innovations, an Intel-GE joint venture company. The Myoscience board of directors would like to thank former CEO Cary Vance for his leadership, strategic guidance, and many contributions during his tenure as Chief Executive Officer at Myoscience. For additional information, please visit http://www.iovera.com or email us directly at mediarelations(at)myoscience.com. ABOUT MYOSCIENCE Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com . © 2018 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience. MKT-0493 REV A For the original version on PRWeb visit: http://www.prweb.com/releases/2018/05/prweb15510469.htm